Episode 295: 294. SGLT2 Inhibitors and Stage 5 CKD

Episode 295: 294. SGLT2 Inhibitors and Stage 5 CKD

SGLT-2 inhibitors have not been evaluated in patients with stage 5 CKD (CKD 5; eGFR, ≤15 mL/minute/1.73 m2). Investigators in Taiwan retrospectively assessed 5 years of outcome data for nearly 48,000 patients with type 2 diabetes and CKD 5 — half of patients had newly initiated SGLT-2 inhibitors, and half were not taking these drugs.

compared with no SGLT2i use, SGLT2i use was associated with lower risks for dialysis (hazard ratio [HR], 0.34 [95% CI, 0.27 to 0.43]), hospitalization for heart failure (HR, 0.80 [CI, 0.73 to 0.86]), AMI (HR, 0.61 [CI, 0.52 to 0.73]), DKA (HR, 0.78 [CI, 0.71 to 0.85]), and AKI (HR, 0.80 [CI, 0.70 to 0.90]), but there was no difference in the risk for all-cause mortality (HR, 1.11 [CI, 0.99 to 1.24]). So almost higher rates of mortality if you are betting man with 95% confidence

https://www.acpjournals.org/doi/10.7326/M23-1874

Jaksot(385)

Episode 375: 386. Could half dose anticoagulation be the answer?

Episode 375: 386. Could half dose anticoagulation be the answer?

Estimated 5-year incidence of recurrent VTE was similar in the reduced-dose and full-dose groups (2.2% and 1.8%). Estimated 5-year bleeding incidence was significantly lower with reduced-dose than wi...

14 Maalis 20258min

Episode 374: 385. PRACTICE CHANGER! Male-Partner Treatment to Prevent Recurrence of Bacterial Vaginosis

Episode 374: 385. PRACTICE CHANGER! Male-Partner Treatment to Prevent Recurrence of Bacterial Vaginosis

https://www.nejm.org/doi/full/10.1056/NEJMoa2405404NNT of 4! systemic metronid and topical clinda bid for one week

12 Maalis 20256min

Episode 373: 384. Chronic Kidney Disease and Empagliflozin Legacy Effect

Episode 373: 384. Chronic Kidney Disease and Empagliflozin Legacy Effect

What Was Studied?The EMPA-KIDNEY trial followed 6,609 CKD patients at risk of disease progression. Participants were randomly assigned to receive empagliflozin (10 mg daily) or a placebo for a median ...

11 Maalis 20259min

Episode 372: 383. What is the GFR at which we stop metforin?

Episode 372: 383. What is the GFR at which we stop metforin?

Metformin while not necessarily first line therapy for diabetes depending on the patients co-morbid conditions it is certainly highly ranked on the list of medications! I know often metformin is stopp...

6 Maalis 202510min

Episode 371: 382. Is it safe to give the flu and covid vaccine at the same time?

Episode 371: 382. Is it safe to give the flu and covid vaccine at the same time?

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2825813Conclusions and Relevance  In this randomized clinical trial assessing simultaneous vs sequential administration of mRNA COVID-19 an...

4 Maalis 20257min

Episode 370: 381. Relative efficacy of prehabilitation interventions and their components

Episode 370: 381. Relative efficacy of prehabilitation interventions and their components

https://www.bmj.com/content/388/bmj-2024-081164systematic review and meta-analysis on prehabilitation before surgery, published in the BMJ in February 2025.Prehabilitation aims to prepare patients for...

27 Helmi 20257min

Episode 369: 380. REPOST mammo part 2

Episode 369: 380. REPOST mammo part 2

Mammograms

24 Helmi 202520min

Episode 368: 379. REPOST mammogram part 1

Episode 368: 379. REPOST mammogram part 1

379. REPORT mammogram part 1

18 Helmi 202519min

Suosittua kategoriassa Terveys ja hyvinvointi

unicast
psykopodiaa-podcast
voi-hyvin-meditaatiot-2
vakeva-elama-viisaampi-mieli-vahvempi-keho
tiedenaiset-podcast
rss-pitaisko-erota
rss-narsisti
puhu-muru
rss-kuumilla-aalloilla
rss-pt-paahtio
meditaatiot-suomeksi
selviytyjat-tarinoita-elamasta
terapiassa
fitnesskulmapodcast
junnut-pelissa
rss-nautinto
audio-sport-juoksu
fitnessvastaanotto
rss-addiktit
rss-seuraava-potilas